ATAI Life Sciences N.V. — Proxy Solicitation & Information Statement 2025

Jun 3, 2025

DEFA14A 1 ef20050097_formdefa14a.htm DEFA14A Licensed to: Broadridge Financial Solutions, LLC Document created using Broadridge PROfile 25.5.1.5318 Copyright 1995 - 2025 Broadridge

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

Filed by the Registrant ☒

Filed by a party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

☐ Definitive Additional Materials

☒ Soliciting Material under § 240.14a-12

ATAI LIFE SCIENCES N.V.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required

☐ Fee paid previously with preliminary materials

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

June 2, 2025

Disclaimer All references in this presentation to “we”, “us”, “our”, “ atai”, or the “Company” refer to ATAI Life Sciences N.V. and its consolidated subsidiaries, unless the context otherwise requires. This presentation contains forward-looking stateme nts within the meaning of the private Securiti es Litigation Reform Act of 1995. We intend such forward-looking statements to be covered under by the safe harbor provisions for forward- looking stateme nts contained in Secti on 27A of the Securiti es Act of 1933, as amended, and Section 21 E of the Securiti es Exchange Act of 1934, as amended.” All statements other than statements of historical facts contained in this prese ntation, including statem ents r egarding our future results of operations and financial position, industry dynamics, business strategy and plans, anticipated milestones and timelines for our non-clinical, pre-clinical studies and clinical trials and our objectives for future operations, are forward-looking statements. The se statem ents r epre sent our opinions, expectations, beliefs, intentions, esti mates or strategies regardi ng the future, which may not be reali zed. In some cases, you can identify forward-looking stateme nts by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these term s or other similar expr essions that are intended to identify forward-looking stateme nts. Forward-looking stateme nts are based largely on our current expe ctations and projections about future events and financial trend s that we believe may affect our financial condition, results of operations, business strategy, short term and long-term business operations and objectives and financial needs. These forward-looking stateme nts are subject to a number of risks, uncertainties and assumptions, including without limitation the important factors described in the section titled “Risk Factors” in our most recent Annual Report on Form 10 -K filed with the Securities and Exchange Commission (“SEC”), as updated by our subseque nt filings with the SEC, that may cause our actual results, perfor mance or achieve ments to differ materially and adversely from those expressed or implied by the forward-looking stateme nts. Moreover, we operate in a very competitive and rapidly changing environm ent. N ew risks emer ge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from tho se contained in any forward-looking stateme nts we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking stateme nts. We caution you therefor e against relying on these forward-looking stateme nts, and we qualify all of our forward-looking stateme nts by these cautionary statements. The forward-looking statements included in this presentation are made only as of the date hereof. Although we believe that the expectations reflected in the forward-looking stateme nts are r easonable, we cannot guarantee that the future r esults, levels of activity, performance or events and circumstances reflecte d in the forward-looking statements will be achieved or occur. Moreover, neither we nor our advisors nor any other person assum es responsibili ty for the accuracy and completeness of the forward-looking statements. Neither we nor our advisors undertake any obligation to update any forward-looking stateme nts for any reason after the date of this presentation to conform these statements to actual results or to changes in our expe ctations, except as may be requi red by law. You should read this presentation with the understanding that our actual future results, levels of activity, performance and events and circumstances may be mater ially differe nt from what we expect. Unless otherwise indicated, information contained in this presentation concerning our industry, competitive position and the markets in which we operate is based on information from independent industry and rese arch organizations, other third-party sources and management esti mates. Manageme nt estimates are der ived from publicly available information released by indepe ndent industry analysts and other third- party sources, as well as data from our internal research, and are based on assumptions made by us upon r evie wing such data, and our exper ience in, and knowledge of, such industry and markets, which we beli eve to be reasonable. In addition, projections, assumptions and estimates of the future perfor mance of the industry in which we operate or of any individual competi tor and our future performance are necessarily subject to uncertainty and risk due to a variety of factors, including those described above. These and other factors could c ause results to differ materially from those expresse d in the estim ates made by independent parties and by us. Industry publications, research, surveys and studies generally state that the information they contain has been obtained from sources believed to be reliable , but that the accuracy and complete ness of such information is not guaranteed. Forecasts and other forward-looking information obtained from these sources are subj ect to the same qualifications and uncertainties as the other forward-looking stateme nts in this presentation. This pr esentation contains excer pts of testimonials from individuals who have been treate d with compounds or derivatives of t he compounds underlying our product candidates in the context of third-party studies or otherwise that are solely intended to be illustrative and not r epre sentative of the potential for beneficial results of such compounds. Our product candidates are in preclini cal or clinical stages of development and none of our product candidates have bee n approved by the FDA or any other regulator y agency. When discussing patents in this presentation, “issued” is to be understood to mean one or more issued or granted claims in one or more country, and “pending” is understood to mean one or more claims pending in a patent application in one or more country. Patent protection is a highly fact-sensitive inquiry, varying from country-to-countr y, and provides for enforceable protecti on to the extent (a) covered by a given claim, and (b) issued in such country or countries. No generalized descriptions of patents made herein should be relied upon; rather, a detailed discussion of our intellectual property and related risk factors can be found in our most r ecently filed Annual Report on Form 10-K, available on the SEC’s website at www.sec.gov. Any trademarks included herein are the proper ty of the owner s thereof and are used for refe rence purposes only. Such use shou ld not be construed as an endorsement of the products or ser vices of the Company. 2

3 Stronger together, atai life sciences and Beckley Psytech unlock value for patients and shareholders Experienced management team Fully owned pipeline with first-in-class potential Multiple near-term milestones Commercially scalable psychedelic therapies Strong IP portfolio Long-term financial synergies Focused pipeline of rapid-acting, accessible psychedelic therapies for mental health

1. Lock-up holders may not sell or transfer shares befor e the later of (a) 60 days following the public announcement of the Phase 2b study or (b) transaction closing (the “Lock-Up Period”). Upon the expiry of the Lock-Up Peri od lock-up holders shall cease to be restricted at a rate of 1/12th of each lock-up holders’ securities per month. Refer to the stock purchase agreement for additional details. 4 atai-Beckley Business Combination Highlights Consideration BPL-003 Data Transaction Closing and Conditions Combined Company will be led by atai’s CEO Srinivas Rao and the executive team will be a combination of atai and Beckley management The Combined Company board will include two nominations from Beckley Psytech shareholders Management & Board atai’s Board recommendation is subject to the following BPL-003 Phase 2b success criteria: Statistical significance achieved on the primary endpoint (MADRS) of the Phase 2b study of BPL-003 with a p<0.05 All-stock deal Non-atai Beckley Psytech shareholders will receive ~105.0M newly issued shares of atai common stock (~31% of pro forma entity) ELE-101 program will be carved out into a separate entity prior to deal close and distributed to Beckley shareholders (including atai) on a pro rata basis Closing expected 2H 2025, subject to atai shareholder approval Beckley Psytech shareholders have voted in favour of the transaction and ~25% of atai’s common stock have entered into voting agreements in support of the transaction Non-atai Beckley Psytech shareholders and Apeiron have entered into lock-up agreements, restricting the sale or transfer of their shares in the combined company following the public announcement of the results of the Phase 2b study of BPL-0031 Less than 3 individual cases of drug related serious adverse events observed in the 8mg arm during the Phase 2b study Less than a total of 6% drug related serious adverse events observed in the 12mg arm during the Phase 2b study

5 Anne Johnson, CPA Chief Financial Officer Rob Conley, M.D. Chief Research & Development Officer Gerd Kochendoerfer, Ph.D. Chief Operating Officer Experienced management team with deep CNS, psychedelic and drug development expertise Cosmo Feilding Mellen Co-founder and Chief Strategy Officer1 Glenn Short, Ph.D. Chief Scientific Officer Srinivas Rao, M.D., Ph.D. Co-founder and Chief Executive Officer Kevin Craig, M.D. Chief Medical Officer 1. Cosmo Feilding Mellen will be nominatedat deal close to be a member of the Combined Company’s Supervisory Board. He will be formally delegated to participate on the Executive Management Team as Chief Strategy Officer.

Combined vision is being delivered through a pipeline of fully-owned psychedelic development programs across a range of compounds and psychiatric indications Abbreviations: DMT = Dimethyltryptamine; R-MDMA = R enantiomer of 3,4-Methylened ioxymethamphetamine Programs Primary Indication Preclin Phase 1 Phase 2 Phase 3 Treatment Resistant Depression (TRD) Social Anxiety Disorder (SAD) TRD VLS-01 DMT EMP-01 R-MDMA BPL-003 Mebufotenin (5-MeO-DMT) benzoate Post-merger Fully-Owned Programs Undisclosed Novel 5-HT2A Receptor Agonists (inc. non-hallucinogenic neuroplastogens) 6

Fully funded through multiple near-term milestones ACHIEVED AND ANTICIPATED UPCOMING MILESTONES1,2 Q2’25 Q1’25 Q3’25 Q4’25 Q1’26 Ph 2b (CIAS) data RL-007 Pro-cognitive neuromodulator Ph 2a (SAD) initiation Ph 2a (SAD) data EMP-01 R-MDMA Ph 2 (TRD) data Ph 2 (TRD) trial initiation ✓ VLS-01 DMT Ph 2b (TRD) data Ph 2a (TRD) SSRI OL data Ph 2a (AUD) OL data ✓ BPL-003 Mebufotenin benzoate Programs Abbreviations: OL = Open-lab el; TRD = Treatment Resistant Depression; SAD = Soci al Anxiety Disorder; AUD = Alcoh ol Use Disor der ; CIAS = Cognitive Impairment Asso ciated with Sch izophreni a 1. All timing provided is estimat ed; 2. Trial initiation d efined as central regulat ory and ethics appro val 7 ✓ ✓

Market Opportunity and Unmet Need INTERVENTIONAL PSYCHIATRY

Leading interventional psychiatry treatment, SPRAVATO® (esketamine) for TRD, achieved blockbuster status in 2024 (>$1B) with ~86% of sales in the US 9 2-hour dosing protocol with established infrastructure Patients monitored for at least 2 hours at each treatment session Delivered intranasally under the supervision of a healthcare provider >5,000 certified clinics1 ~40-50K US patients treated in 20242 Potential for many administrations per year Weeks 1 to 4: twice per week Weeks 5 to 8: once weekly Week 9 and after: every two weeks or once weekly https://ww w.spravato.com/sprav ato-av ailab le-treatment-centers/ Based on global annual sales and gross to net pricing assumptions Johnson&J ohnson Q4 an d Full-Year 2024 Results: https://w ww.investor.jnj.com/ new s/news -details/2025/Johnson--Johnson-Repor ts-Q4-and-Full-Year-2024-Results/default.aspx $198M $328M $589M $929M $100M $148M $0M $250M $500M $750M $1,000M $1,250M Spravato® –ReportedGlobal Annual Sales3 (2021-24) $26M 2021 22 23 24 $46M $224M $374M $689M $1,077M RestofWorld US SPRAVATO® interventional psychiatry treatment paradigm J&J now highlights SPRAVATO® as a “key franchise” guiding $3 billion to $3.5 billion in annual sales

DEVELOPED TO PROVIDE RAPID AND DURABLE EFFICACY WITH A SHORT TIME-IN-CLINIC Novel psychedelic treatments

BPL-003 and VLS-01 are novel psychedelic candidates developed to optimize patient access for TRD with a short time-in-clinic Abbreviations: TRD = Treatment Resistant Depression; IND = Investigational New Drug Application; COM = Com position of Matter 1. Dourron HM, Nichols CD, Simonsson O, Bradley M, Carhart-Harris R, Hendricks PS. 5-MeO-DMT: An atypical psychedelic with unique pharma cology, phenomenology & risk? Psychopharma cology (Berl). 2023 Dec TARGET POSITION First-in-class and best-in-class for mebufotenin First-in-class and best-in-class for DMT PHARMACOLOGY (5-HT2A : 5-HT1A binding affinity1) 5-HT1A/5-HT2A receptor agonist (1 : 0.009) 5-HT2A receptor agonist (1 : 3.4) FORMULATION Dry Powder Nasal Spray (transmucosal) Buccal Film (transmucosal) TREATMENT DURATION ~2 hours ~2 hours DEVELOPMENT STAGE Phase 2b; topline data anticipated mid ’25 IND approved Phase 2; topline data anticipated Q1 ’26 IND approved INTELLECTUAL PROPERTY US COM and Methods issued; additional pending US COM and Methods issued; additional pending VLS-01 Dimethyltryptamine BPL-003 Mebufotenin benzoate 11

BPL-003 and VLS-01 designed to leverage SPRAVATO® 2-hour in-clinic treatment paradigm in depression 12 0 4 8 12 ANTICIPATEDTIME TO DISCHARGE FROMCLINIC POST-DOSE 1 (inhours)Ilustrative SPRAVATO® BPL-003 Multi-dose Psilocybin 5-MeO- +analogs DMT MDMA LSD Average workday (8hours) ~2 ~2 ~2 ~1 to3* ~6 ~8 ~8 to12 VLS-01 Subject to further validation through future clinical studies and real-world evidence w ww.spravatohcp.com/#find-a-center * If multi-dose required KEY TAKEAWAYS Predictable 2-hour treatment: the potential to fit into the 2-hour in-clinic treatment paradigm established by SPRAVATO Potential extended durability reduces patient burden: 1-2 doses of a psychedelic therapy provides a sustained effect, simplifying the dosing schedule compared to SPRAVATO’s once-weekly regimen Significantly improves use of infrastructure: lower dosing frequency compared to SPRAVATO could lower provider burden, and improve payer receptivity

INTRANASAL MEBUFOTENIN BENZOATE FOR TRD & AUD BUSINESS COMBINATION WITH BECKLEY PSYTECH BPL-003

BPL-003 Phase 1 Results BPL-003 PHASE 1 RESULTS KEY TAKEAWAYS 30 25 20 15 10 5 0 0 2 4 6 8 10 PK/PD results demonstrated a dose proportional profile with perceptual effects generally resolving <90 minutes Pharmacokinetics (PK) Exposure was dose-proportional Rapid onset with mean Tmax of 6-17 min Mean half life of 15-30 min Pharmacodynamics (PD): Participants were psychedelic naive All participants on doses ≥6mg achieved intensity scores ≥7 Perceptual effects generally fully resolved within <90 mins 12mg (n=5) 10mg (n=5) 8mg (n=5) 6mg (n=4) 4mg (n=4) 2.5mg (n=4) 1mg (n=4) Mean plasma concentration level (ng/ml) Time post-dose (minutes) 60 0 12 30 Time post-dose (minutes) 60 90 Mean SDI (1 to 10) 0 12 30 90 Dose range taken forward to Phase 2 BPL-003 Phase 1 PK Profile BPL-003 Phase 1 Subjective Drug Intensity (SDI) Rating 12mg (n=5) 10mg (n=5) 8mg (n=5) 6mg (n=4) 14 PK: Pharmacokinetic

BPL-003 Completed Part 1 & Part 2 of the open-label Phase 2a study investigating BPL- 003 in patients with TRD Phase 2a Clinical Trial Design Key Inclusion Criteria: Montgomery-Asberg Depression Rating Scale (MADRS) score ≥24 Part 1 & 3: willing and able to discontinue current antidepressants Part 2: on current stable dose of antidepressant SSRI therapy Key Objectives: Primary Endpoint: Safety and tolerability of BPL-003 Other Secondary Endpoints: MADRS change through Week 12 Remission and response rates through Week 12 Study Details: Open-label study evaluating a single dose of BPL-003 nasal spray, in patients with moderate-to-severe TRD Parts 1 & 3 are in patients not on anti-depressants, Part 2 is in patients who are also taking select SSRIs to explore effects of co-administration Psychological support during preparation, dosing and integration S cr e e nin g Par t 1 : M on ot he r a py O p e n l a b e l Day 2 85 C omp le t e d Q 1 2 0 24 S i ngle do s e o f BPL- 00 3 29 Par t 2 : Adj un ct to SS RIs C omp le t e d Q 2 2 0 25 Par t 3: Tw o- do se i ndu ct io n mo del I ni t i at e d Q 3 2 02 4 15

BPL-003 Phase 2a Part 1 (Monotherapy Cohort) Data MADRS SCORE OVER TIME BPL-003 10 MG SINGLE DOSE KEY TAKEAWAYS Mean MADRS reduction of ~13 points at Day 2, and sustained to Day 85 55% of patients met response criteria1 one day after a single 10mg dose of BPL-003 55% of patients met clinical remission criteria2 one month after a single dose Improvements broadly sustained for 3 months after dosing with 45% of subjects meeting remission criteria at day 85 Patients were deemed ready for discharge within an average time of less than 2 hours Rapid & durable clinical response and remission induced in over 50% of patients following a single dose of BPL-003 monotherapy Interim analysis of the per protocol population (n=11) Response defined as ≥50% improvement in MADRS score Remission defined as MADRS score ≤10 16

Initial data from the adjunctive/SSRI cohort is broadly consistent with monotherapy data BPL-003 Phase 2a Part 2 (Adjunct to SSRIs) Initial Data MADRS SCORE OVER TIME BPL-003 SINGLE DOSE (ADJUNCTIVE) KEY TAKEAWAYS Participants with moderate-severe depression having failed 2 prior therapies and on a single SSRI Mean MADRS reduction of 19 points at Day 29 with 18-point reduction at Day 85 No new safety signal identified Tolerability profile appears consistent with monotherapy dosing 17 Response defined as ≥50% improvement in MADRS score; Remission defined as MADRS score ≤10

Drug Related TEAEs TOTALa N subjects (%) [N events]b Administration site discomfortc 10 (41.7%) [141#] Nausea 5 (20.8%) [51#] Vomiting 5 (20.8%) [55#] Other events (<10% frequency) 8 (33.3%) [83#, 1] TOTAL 14 (58%) [32] BPL-003 Phase 2a Part 1 & 2 Safety DRUG RELATED TEAES KEY TAKEAWAYS 97% of events were mild or moderate and there were no Serious Adverse Events (SAEs) ~90% of drug-related AEs occurred on the day of dosing, and all were resolved without intervention AE profile of BPL-003 in TRD subjects is similar to that seen in healthy volunteers In Phase 2a, BPL-003 was well-tolerated as monotherapy and adjunctive treatment in TRD patients with transient events and no Serious AEs observed Combined Drug Related TEAEs from Part 1 & 2 (n=24) Events were mild unless labelled. #Moderate events. Severe event Administration site discomfort includes the preferred terms administration site irritation, administration site pain, administration site discharge, administration site erythema and nasal discomfort TEAE =Treatment emergent adverse events 18

BPL-003 BPL-003 randomized, quadruple-masked, monotherapy Phase 2b study in moderate to severe TRD patients Phase 2b Clinical Trial Design Key Inclusion Criteria: Patients with moderate to severe TRD Hamilton Depression Scale (HAM-D) >= 19 Willing and able to discontinue current antidepressants Key Objectives: PRIMARY ENDPOINT: MADRS change from baseline at Week 4, 12mg vs. 0.3mg OTHER SECONDARY ENDPOINTS: Remission and responder rates MADRS change from baseline at Day 2, Week 1 & Week 8 MADRS change from baseline for 8mg vs 0.3mg 1. Patients entering the open-lab el extension are randomized to receive either a single 12mg dose or a biphasic 4mg and 8mg dose approximately 10 minutes apart. Abbreviations: MADRS = Montgomery–Åsberg Depression Rating Scale; CGI-S = Clinica l Global Impressions-Severity ; PGIC = Patient's Glob al Impression of Change; EQ-5D = EuroQol-5D 19 TRIAL STATUS En ro lmen t co mpl et ed To pli ne data anti ci pated mi d - 2 02 5 Randomization (n=~196) Day 0 Wk-8 Washout 12 mg1 Core Study ( 8 weeks) 1st Primary Dose Analysis 57 Open Label Extension ( 8 weeks) 1 2 8 29 57 1 2 29 2nd Dose 0. 3 mg ( n=~7 0) 8 mg ( n=~45) 12 mg ( n=~7 0)

BPL-003 Strong IP portfolio with coverage out to 2043 20 BPL-003 has superior properties that are novel and non-obvious, compared to other salt forms Higher permeation, less irritation, greater stability, dose-proportional PK These novel and non-obvious properties have enabled us to build strong IP protection around BPL-003 Multiple composition of matter and methods of use (including in depression) patents granted in US, Europe & UK covering mebufotenin benzoate salt and the most stable polymorph thereof (2040/1 expiry) A granted US composition of matter patent covering the formulation of BPL-003 intended for Phase 3 (earliest expiry 2043) Additional patents covering composition of matter, methods of synthesis, methods of use, crystalline forms and formulations pending in US, Europe & RoW Patent Term Extensions and Supplementary Protection Certificates will be sought, where available Regulatory exclusivity provides additional protection IP Overview

Summary + Q&A

Together, atai Life Sciences and Beckley Psytech will create impactful psychedelic treatments addressing significant unmet needs in mental health 22 Short treatment time, patent-protected: BPL-003 potential to be a first-in- class mebufotenin benzoate therapy; and VLS-01, potential best-in-class route of administration and tolerability for DMT 1 Near-term catalysts: BPL-003 Phase 2b readout anticipated midyear, additional Phase 2 data readouts anticipated over the next 12 months 2 Simplified & synergistic corporate structure: single public entity fully unlocks value of atai and Beckley Psytech’s teams and assets 3

23

Forward-looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “anticipate,” “initiate,” “could,” “would,” “project,” “plan,” “potentially,” “preliminary,” “likely,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things: expectations regarding the closing of the transaction, including timing and approvals; expectations regarding operations of the combined company, including strategic value of the clinical development programs for patients and shareholders as well as expectations regarding financial synergies; timing and results of Beckley’s BPL-003 Phase 2b trial and related data readouts; expectations regarding Beckley’s other clinical assets, including ELE-101; expectations regarding the concurrent private placement, including related closing conditions; our business strategy and plans; and the potential, success, cost and timing of development of our product candidates, and the product candidates of those companies we invest in.

Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the SEC, as such factors may be updated from time to time in atai's other filings with the SEC. atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.

No Offer or Solicitation

This communication is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

Additional Information and Where to Find It

This communication is being made in respect of the proposed transaction between the Company and Beckley Psytech Limited. In connection with the proposed transaction, the Company will file with the SEC a proxy statement on Schedule 14A (the “Proxy Statement”), as well as other relevant documents regarding the proposed transaction. This press release is not a substitute for the Proxy Statement or any other document which the Company may file with the SEC. INVESTORS ARE URGED TO READ IN THEIR ENTIRETY THE PROXY STATEMENT REGARDING THE TRANSACTION WHEN IT BECOMES AVAILABLE AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.

A free copy of the Proxy Statement, as well as other filings containing information about the Company, when such documents become available, may be obtained at the SEC’s website (http://www.sec.gov).

Participants in the Solicitation

The Company and its directors and executive officers may be deemed to be participants in the solicitation of proxies from its shareholders in respect of the proposed transactions contemplated by the Proxy Statement. Information regarding the persons who are, under the rules of the SEC, participants in the solicitation of the shareholders of the Company in connection with the proposed transactions, including a description of their direct or indirect interests, by security holdings or otherwise, will be set forth in the Proxy Statement when it is filed with the SEC. Information regarding the Company’s directors and executive officers is contained in its Annual Report on Form 10-K for the year ended December 31, 2024 and its Proxy Statement on Schedule 14A, dated April 21, 2025, which are filed with the SEC.